Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Goodwill for the year ending June 30, 2024

Kazia Therapeutics Limited Goodwill is NA for the year ending June 30, 2024. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Kazia Therapeutics Limited Goodwill for the year ending June 30, 2023 was USD 0.00, a 0.00% change year over year.
Kazia Therapeutics Limited Goodwill for the year ending June 30, 2022 was USD 0.00, a 0.00% change year over year.
Kazia Therapeutics Limited Goodwill for the year ending June 30, 2021 was USD 0.00.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years